Breaking News, Financial News

Financial Report: Gilead

Continued uptake of Biktarvy helps offset declines for other products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead 4Q Revenues: $5.9 billion (flat) 4Q Earnings: $2.7 billion (nm)    FY Revenues: $22.4 billion (+1%) FY Earnings: $5.4 billion (-2%) Comments: Product sales for the fourth quarter of 2019 were $4.5 billion in the United States, $840 million in Europe and $440 million in other locations. HIV product sales were $4.6 billion in the quarter, up 12% primarily driven by higher sales volume as a result of the continued uptake of Biktarvy. Chronic hepatitis C virus (HCV) produc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters